Turning Point Brands (TPB) Q2 2026 earnings review
Hypergrowth in Nicotine Pouches at the Expense of Profitability
Turning Point Brands is executing a textbook 'land grab' strategy. Total revenue grew 22.6% YoY to $142.9M, entirely driven by explosive 128% growth in Modern Oral (nicotine pouches). However, management is flooding the P&L with sales and marketing expenses to capture chain store distribution. Consequently, SG&A nearly doubled YoY, collapsing Adjusted EBITDA by 50% to $15.2M and Net Income by 75%. The legacy Zig-Zag business continues to bleed, but the accelerating market share gains in Modern Oral prompted management to drastically raise full-year pouch revenue guidance while keeping EBITDA targets depressed.
🐂 Bull Case
The FRE and ALP brands are scaling massively, accelerating from $30.1M a year ago to $68.4M this quarter. Management confidently raised FY26 net sales guidance for the segment by $50M at the midpoint.
The company raised $59.6M in equity to aggressively fund its distribution and marketing. They are playing to win the category, not just defend margins.
🐻 Bear Case
Adjusted EBITDA was cut in half as SG&A spiked 91%. Capturing major chain accounts requires massive slotting fees and marketing spend that is destroying near-term unit economics.
The legacy Zig-Zag business decelerated further, falling 24.8% YoY. The company is actively sacrificing its former core engine to fund the nicotine pouch pivot.
⚖️ Verdict: ⚪
Neutral. The top-line execution in Modern Oral is phenomenal, validating the product-market fit. However, the sheer cost of acquiring this growth (-50% Adj EBITDA) and the structural decline of Zig-Zag introduces heavy execution risk until the marketing spend normalizes.
Key Themes
Modern Oral (FRE & ALP) Adoption Accelerating
Modern Oral net sales accelerated 128% YoY to $68.4M. This segment now accounts for 48% of total company sales, up from just 26% a year ago. The dual-brand strategy with FRE and ALP is clearly resonating in retail, driving an unprecedented top-line mix shift.
Retail Chain Expansion Strategy
The accelerating sales growth is the direct result of a planned 70% expansion in chain store counts. The company is successfully leveraging its legacy Stoker's distribution relationships to force its way onto shelves previously dominated by Zyn and Rogue.
Macro Shift to Oral Nicotine
Management continues to capitalize on what they term a '>$50 billion generational shift' in nicotine consumption. The rapid decay in combustible products serves as a structural tailwind for the pouch category as users trade down in risk and seek discrete consumption options.
SG&A Investments Crushing Margins
Operating income was devastated by a 91.1% YoY surge in SG&A to $76.9M. This Reversing trend reflects the brutal 'trench warfare' required to win in retail, encompassing expanded sales force costs, massive chain account slotting fees, and marketing partnerships (like TKO/UFC).
Zig-Zag Segment Decay Decelerating Further
The Zig-Zag segment is deteriorating faster than expected. Sales fell 24.8% YoY to $35.4M. While management has historically called this an 'opportunity cost' of pivoting to pouches, the pace of the decline creates a large revenue hole that Modern Oral has to outgrow.
Margin Dilution from Chain Penetration
Contradicting the narrative that scale inherently brings margin expansion, Stoker's adjusted gross margin dropped to 56.9% from 62.5% a year ago. The company explicitly blamed this on 'higher chain penetration,' proving that winning volume in national retailers requires heavy promotional and pricing trade-offs.
Tariff Costs Masked by Refund
Reported Gross Profit artificially spiked 40.6% to $93.7M, but this included an $8.47M out-of-period adjustment for refunded tariffs. Excluding this, gross profit was a more subdued $81.5M. Underlying tariff pressure remains a structural headwind until domestic manufacturing scales.
Other KPIs
Accelerating wildly. Up 91.1% YoY from $40.3M in 25Q2. This single line item explains the 75% drop in Net Income. The company is actively spending its legacy cash flows to buy future market share in the pouch category.
Stable and reinforced. The company ended the quarter with $268.3M in cash and raised $59.6M in fresh equity. This provides a massive war chest to sustain the cash-burning marketing strategy without tripping over the $294.1M in long-term debt.
Accelerating sequentially. Up from 49.1% in the prior year quarter, driven by favorable product mix. While the segment's top-line is shrinking rapidly, the remaining volume is highly profitable.
Guidance
Accelerating. A massive raise from the prior guidance of $210 - $225 million, validating the aggressive sales push and indicating high confidence in H2 retail sell-through.
Accelerating. Raised from $280 - $300 million. The $70-$80 million gap between gross and net sales highlights the massive contra-revenue (slotting fees, promotions) required to maintain shelf space.
Decelerating. Maintained from Q1, this implies a sharp contraction from FY25's $119.5M. Management is purposely capping profitability to fund the Modern Oral 'land grab', warning that the S&M spend will remain elevated.
Key Questions
Margin Dilution Floor
With Stoker's adjusted gross margin compressing to 56.9% due to chain penetration, at what volume threshold does the scale of Modern Oral begin to expand unit economics rather than dilute them?
Zig-Zag Strategy
Zig-Zag sales are down 24.8% YoY. Has the strategy for this segment officially shifted to pure harvest mode, or is there an expected revenue floor where it will stabilize?
Capital Deployment
The $59.6M equity raise provides a robust war chest alongside your cash generation. Are these funds earmarked solely for S&M and the Louisville manufacturing plant, or are strategic acquisitions in the oral category being considered?